Brief introduction of Xinjiang Qi Kang Habowei Medicine Co., Ltd.

Xinjiang Qi Kang Habowei Pharmaceutical Co., Ltd. is a state-level high-tech enterprise specializing in the research, development, production and sales of Uygur medicine, and a designated production enterprise of special commodities for ethnic minorities recognized by the State Ethnic Affairs Commission. The company was registered in Urumqi National High-tech Industrial Development Zone at the end of 2000. It consists of four state-owned legal person shareholders and six natural person shareholders, namely, Xinjiang Asia-Europe Railway Diversification Development Center, Xinjiang Bingtuan Medicine Co., Ltd., Nanjing Medicine Co., Ltd. and Xinjiang Uygur Medicine Research Institute. The actual controlling shareholder is Nanjing Pharmaceutical Co., Ltd., the first listed pharmaceutical circulation enterprise in China, and its annual operating scale is the fourth in China. The registered capital of the company is 57.976 million yuan, and the first-phase production base is located at No.625 Yingbin Road, Urumqi, covering an area of 40,000 square meters. The production base under construction in the second phase is located in the North Industrial Park of High-tech Zone, covering an area of nearly 60,000 square meters. The company produces nearly 30 kinds of medicines in 6 dosage forms, such as oral liquid, tablets, hard capsules, granules, syrup and mixture, and more than 400 kinds of Chinese and Uygur medicine pieces. After the completion of the second production base, the company will form an annual industrial output value of 50- 1 100 million yuan.

Relying on the innovation team of Industry-University-Research with Dr. Hamratti as the chief scientist, the company has developed 9 quasi-brand drugs 19, including 5 national invention patents, 3 national traditional Chinese medicine protected varieties, 4 national medical insurance varieties and 4 varieties under research. * * * applied for 9 invention patents and obtained 7 authorizations; * * * Apply for registered trademark 13 pieces, and authorize 1 1 piece, among which "Qi Kang" trademark won the title of "Xinjiang Famous Trademark". By the end of 20 1 1, the company had * * completed more than 50 topics and projects in China, the autonomous region, Urumqi and high-tech zones, including the SME innovation fund project of the Ministry of Science and Technology, the national torch plan project, the national high-tech industrialization demonstration project, the national major scientific and technological achievements transformation project, the national technological innovation project, the new drug research project of the science and technology department of the autonomous region, the high-tech transformation innovation fund project and the patent implementation of the autonomous region. Around the modern Uyghur medicine industry, the company has established three technological innovation platforms: national postdoctoral research center, autonomous region-level enterprise technology center and municipal Uyghur medicine R&D engineering technology research center. The company invests in research and development expenses every year, accounting for more than 8.2% of the total sales revenue of that year. By the end of 20 1 1, nearly 20 specifications of major Uygur medicine products and exclusive products have been transformed and put into the national market in stages, with the output value of listed products reaching more than 400 million yuan. The company leads the development of Uygur medicine in product research and development, brand creation, marketing network construction and marketing differentiation strategy.

contact information

Company name: Xinjiang Qi Kang Haberwei Pharmaceutical Co., Ltd.

Company Address: No.625 Yingbin Road, Urumqi

Postal code: 830026